Stop-flow technique for loco-regional delivery of antiblastic agents: Literature review and personal experience

European Journal of Surgical Oncology

Volumn 28, Issue 5, 2002, Pages 544-553

  Pilati, P ^a   Mocellin, S ^a   Miotto, D ^a   Rossi, C R ^a   Codello, L ^a   Foletto, M ^a   Scalerta, R ^a   Vieceli, G ^a   Ceccherini, M ^a   Nitti, D ^a   Lise, M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Loco regional chemotherapy; Perfusion; Stop flow technique

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; MELPHALAN; MITOMYCIN C; STARCH MICROSPHERE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; COLORECTAL CANCER; CONTROLLED STUDY; DOG; DRUG DELIVERY SYSTEM; DRUG SAFETY; EXPERIENCE; GASTROINTESTINAL DISEASE; HEALTH STATUS; HEMATOLOGIC DISEASE; HUMAN; LIMB PERFUSION; LUNG CANCER; LYMPHOMA; MEDICAL LITERATURE; MEDLINE; MELANOMA; MORBIDITY; MORTALITY; NEUROLOGIC DISEASE; NONHUMAN; PANCREAS CANCER; PATIENT CARE; PELVIS; PILOT STUDY; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR VASCULARIZATION; VASCULAR DISEASE;

EID: 0036704332     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.2002.1253     Document Type: Article

References (76)

1. Heinemann V. Gemcitabine: progress in the treatment of pancreatic cancer. Oncology 2001; 60: 8-18.
2. Blay JY, Bouhour D, Ray-Coquard I, Dumontet C, Philip T, Biron P. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J Clin Oncol 2000; 18: 3643-50.
3. Sagar PM, Pemberton JH. Surgical management of locally recurrent rectal cancer. Br J Surg 1996; 83: 293-304.
4. Blanke C, Ansari R, Mantravadi R et al. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol 1995; 13: 1425-9.
5. Gunderson LL, Martin JK, O'Connell MJ, Beart RW, Kvols LK, Nagorney DM. Local control and survival in locally advanced gastrointestinal cancer. Int J Radiat Oncol Biol Phys 1986; 12: 661-5.
6. Engenhart-Cabillic R, Debus J, Prott FJ et al. Use of neutron therapy in the management of locally advanced nonresectable primary or recurrent rectal cancer. Recent Results Cancer Res 1998; 150: 113-24.
7. Kelsen D, Atiq OT. Therapy of upper gastrointestinal tract cancers. Curr Probl Cancer 1991; 15: 235-94.
8. Buzaid AC, Murren J. Chemotherapy for advanced malignant melanoma. Int J Clin Lab Res 1992; 21: 205-9.
9. Sessa C, Aamdal S, Wolff I et al. Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group. Ann Oncol 1994; 5: 471-2.
10. Creech O Jr, Krementz E. Techniques of regional perfusion. Surgery 1966; 60: 938-47.
11. Kerr DJ, Los G. Pharmacokinetic principles of locoregional chemotherapy. Cancer Surv 1993; 17: 105-22.
12. Rossi CR, Foletto M, Di Filippo F et al. Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion. Cancer 1999; 86: 1742-9.
13. Lienard D, Eggermont AM, Koops HS et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999; 9: 491-502.
14. Alexander HR, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998: 16: 1479-89.
15. Burt ME, Liu D, Abolhoda A et al. Isolated lung perfusion for patients with unresectable metastases from sarcoma: a phase I trial. Ann Thorac Surg 2000; 69: 1542-9.
16. Aigner K. Aortic stop-flow infusion (ASI) and hypoxic abdominal perfusion (HAP) for disseminated bulk peritoneal carcinomatosis: rationale and technique. Reg Cancer Treat 1993; 6: 3.
17. Scheffer GL, Wijngaard PL, Flens MJ et al. The drug resistance-related protein LRP is the human major vault protein. Nat Med 1995; 1: 578-82.
18. el-Deiry WS. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol 1997; 9: 79-87.
19. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDRI/gp17O expression and its possible functional significance. J Natl Cancer Inst 1997; 89: 917-31.
20. Hryniuk WM, Figueredo A, Goodyear M. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 1987; 14: 3-11.
21. Muchmore JH. Regional chemotherapy plus hemoflltration for the treatment of regionally advanced malignancy. Cancer 1996; 78: 941-3.
22. Patt YZ, Peters RE, Chuang VP, Wallace S, Claghorn L, Mavligit G. Palliation of pelvic recurrence of colorectal cancer with intra-arterial 5-fluorouracil and mitomycin. Cancer 1985; 56: 2175-80.
23. Di Filippo F, Anza M, Rossi CR et al. The application of hyperthermia in regional chemotherapy. Semin Surg Oncol 1998; 14: 215-23.
24. Pilati P, Rossi CR, Mocellin S et al. Multimodal treatment of peritoneal carcinomatosis and sarcomatosis. Eur J Surg Oncol 2001; 27: 125-34.
25. Buroker T, Samson M, Correa J, Fraile R, Vaitkevicius VK. Hepatic artery infusion of 5-FUDR after prior systemic 5-fluorouracil. Cancer Treat Rep 1976; 60: 1277-9.
26. Karakousis CP, Kanter PM, Lopez R, Moore R, Holyoke ED. Modes of regional chemotherapy. J Surg Res 1979; 26: 134-41.
27. Averbach AM, Stuart OA, Sugarbaker TA et al. Intraaortic stop-flow infusion: pharmacokinetic feasibility study of regional chemotherapy for unresectable gastrointestinal cancers. Ann Surg Oncol 1995; 2: 325-31.
28. Arredondo MA, Chaudhuri B, Kar R, Crist KA, Thomford NR, Chaudhuri PK. Isolated perfusion of pancreas with mitomycin C. Am J Surg 1990; 159: 569-74.
29. Kemeny NE, Ron IG. Hepatic arterial chemotherapy in metastatic colorectal patients. Semin Oncol 1999; 26: 524-35.
30. Link KH, Kornmann M, Formentini A et al. Regional chemotherapy of non-resectable liver metastases from colorectal cancer - literature and institutional review. Langenbecks Arch Surg 1999; 384: 344-53.
31. Nitti D, Da Pian P, Pilati P et al. Hepatic arterial infusion (HAI) for unresectable liver metastases (ULM) from colorectal carcinoma. Tumori 1997; 83: S61.
32. Cohen AM, Kemeny NE, Kohne CH, Wils J, de Takats PG, Kerr DJ. Is intra-arterial chemotherapy worthwhile in the treatment of patients with unresectable hepatic colorectal cancer metastases? Eur J Cancer 1996; 32A: 2195-205.
33. Lorenz M, Muller HH. Randomized, multicenter trial of fiuorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fiuorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000; 18: 243-54.
34. Skarsgard LD, Skwarchuk MW, Vinczan A, Kristl J, Chaplin DJ. The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res 1995; 15: 219-23.
35. Pruijn FB, van Daalen M, Holford NH, Wilson WR. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1997; 39: 541-6.
36. de Wilt JH, Manusama ER, van Tiel ST, van Ijken MG, ten Hagen TL, Eggermont AM. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 1999; 80: 161-6.
37. Teicher BA, Lazo JS, Sartorelli AC. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 1981; 41: 73-81.
38. Kruskal JB, Hlatky L, Hahnfeldt P, Teramoto K, Stokes KR, Clouse ME. In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J Vasc Interv Radiol 1993; 4: 741-7.
39. Kennedy KA, Siegfried JM, Sartorelli AC, Tritton TR. Effects of anthracyclines on oxygenated and hypoxic tumor cells. Cancer Res 1983; 43: 54-9.
40. Bush RS, Jenkin RD, Allt WE et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer Suppl 1978; 37: 302-6.
41. Rockwell S. Effect of some proliferative and environmental factors on the toxicity of mitomycin C to tumor cells in vitro. Int J Cancer 1986; 38: 229-35.
42. Aigner KR. Intra-arterial infusion: overview and novel approaches. Semin Surg Oncol 1998; 14: 248-53.
43. Kar R, Cohen RA, Terem TM, Nahabedian MY, Wile AG. Pharmacokinetics of 5-fluorouracil in rabbits in experimental regional chemotherapy. Cancer Res 1986; 46: 4491-5.
44. Klein ES, Ben-Ari GY, Papa MZ, Adar R, Bass A. Vascular complications of total abdominal perfusion and aortic stop-flow infusion. J Surg Oncol 1996; 61: 17-19.
45. Guadagni S, Fiorentini G, Palumbo G et al. Hypoxic pelvic perfusion with mitomycin C using a simplified balloon-occlusion technique in the treatment of patients with unresectable locally recurrent rectal cancer. Arch Surg 2001; 136: 105-12.
46. Lygidakis NJ, Dedemati G, Spenzaris N, Theodoropoulou M. Unresectable pancreatic cancer: is a multi-modality aprroach a promising therapeutical alternative? Hepatogastroenterology 1997; 44: 1222-8.
47. Turk PS, Belliveau JF, Darnowski JW, Weinberg MC, Leenen L, Wanebo HJ. Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique. Arch Surg 1993; 128: 533-8, discussion 538-9.
48. Wanebo HJ, Chung MA, Levy AI, Turk PS, Vezeridis MP, Belliveau JF. Preoperative therapy for advanced pelvic malignancy by isolated pelvic perfusion with the balloon-occlusion technique. Ann Surg Oncol 1996; 3: 295-303.
49. Thompson JF, Liu M, Waugh RC et al. A percutaneous aortic 'stop-flow' infusion technique for regional cytotoxic therapy of the abdomen and pelvis. Reg Cancer Treat 1994; 7: 202-7.
50. Roversi R, Ricci S, Rossi G, Cavallo G, Roversi M, Fiorentini G. Results of flow-controlled antiblastic perfusions (stop-flow technique) carried out with percutaneous technique: 30-month experience. [in Italian] Radiol Med (Torino) 1997; 93: 732-8.
51. Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 1998; 14: 238-47.
52. Fiorentini G, Poddie D, S R. Intra-aortic stop flow infusion (IASFI) with hypoxic abdominal perfusion (HAP) in UICC stage III/IV pancreatic carcinoma (PC): report of a phase II study. Reg Cancer Treat 1996; 9: 88-91.
53. Lygidakis NJ, Safioleas M, Sgourakis G, Aphinives P. Stop-flow thoracic perfusion for unresectable pulmonary carcinoma with or without inhalation IL-2 immunotherapy. A prospective randomized study. Hepatogastroenterology 1999; 46: 792-8.
54. Lorenz M, Heinrich S, Staib-Sebler E et al. Regional chemotherapy in the treatment of advanced pancreatic cancer - is it relevant? Eur J Cancer 2000; 36: 957-65.
55. Stefano G, Filippo R, Giuseppe A et al. Stop-flow in mediastinum and thorax for resistant lymphoma. Hepatogastroenterology 2000; 47: 378-82.
56. Guadagni S, Aigner KR, Palumbo G et al. Pharmacokinetics of mitomycin C in pelvic stopflow infusion and hypoxic pelvic perfusion with and without hemofiltration: a pilot study of patients with recurrent unresectable rectal cancer. J Clin Pharmacol 1998; 38: 936-44.
57. Bachur NR, Gordon SL, Gee MV, Kon H. NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci USA 1979; 76: 954-7.
58. Crooke ST, Bradner WT. Mitomycin C: a review. Cancer Treat Rev 1976; 3: 121-39.
59. Tannock I. Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep 1978; 62: 1117-33.
60. Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982; 18: 905-10.
61. Lygidakis NJ, Sgourakis G, Aphinives P. Upper abdominal stop-flow perfusion as a neo and adjuvant hypoxic regional chemotherapy for resectable gastric carcinoma. A prospective randomized clinical trial. Hepatogastroenterology 1999; 46: 2035-8.
62. Aigner KR, Gailhofer S, Brammer C. Abdominal stop flow infusion breaks drug resistance in systemically pretreated progressive FIGO IIIc and IV ovarian cancer. Gan To Kagaku Ryoho 1998; 25: 111-14.
63. Aigner KR, Gailhofer S, Kopp S. Regional versus systemic chemotherapy for advanced pancreatic cancer: a randomized study. Hepatogastroenterology 1998; 45: 1125-9.
64. Lorenz M, Petrowsky H, Heinrich S et al. Isolated hypoxic perfusion with mitomycin C in patients with advanced pancreatic cancer. Eur J Surg Oncol 1998; 24: 542-7.
65. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
66. Nakajima Y, Horikawa M, Kin T et al. Hyperthermo-chemo-hypoxic isolated liver perfusion for hepatic metastases: a possible adjuvant approach. Recent Results Cancer Res 1998; 147: 28-41.
67. Horikawa M, Nakajima Y, Kido K, Ko S, Ohashi K, Nakano H. Simple method of hyperthermo-chemo-hypoxic isolated liver perfusion for hepatic metastases. World J Surg 1994; 18: 845-50, discussion 851.
68. Goss P, Parsons PG. The effect of hyperthermia and melphalan on survival of human fibroblast strains and melanoma cell lines. Cancer Res 1977; 37: 152-6.
69. Overgaard J. Combined adriamycin and hyperthermia treatment of a murine mammary carcinoma in vivo. Cancer Res 1976; 36: 3077-81.
70. Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res 1980; 40: 1165-8.
71. Baba T, Aoki K, Kidera Y, Kimura M, Kanematsu T. Temporary interruption of regional blood flow combined with local hyperthermia for cancer chemotherapy. Cancer Res 1976; 36: 2146-52.
72. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 2000; 60: 1197-201
73. Eggermont AM, Schraffordt Koops H, Klausner JM et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 224: 756-64, discussion 764-5.
74. Nakamoto T, Inagawa H, Takagi K, Soma G. A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors. Anticancer Res 2000; 20: 4087-96.
75. Eggermont AM, van IMG, van Etten B et al. Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: from laboratory to the clinic towards a percutaneous procedure. Hepatogastroenterology 2000; 47: 776-81.
76. van Ijken MG, de Bruijn EA, de Boeck G, ten Hagen TL, van der Sijp JR, Eggermont AM. Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs. Ann Surg 1998; 228: 763-70.